

Amendments to the Claims

1-6. (Cancelled)

7. (Currently Amended) Isolated and purified biologically active TFPI made by a method comprising:

transforming yeast cells with a vehicle, said vehicle comprising a first nucleotide sequence encoding a first protein, wherein the first protein is TFPI, wherein the N-terminal amino acid sequence of the TFPI is SEQ ID NO: 7, said first nucleotide sequence being immediately preceded in frame by a second nucleotide sequence encoding a second protein, the first and second nucleotide sequences together encoding a fusion protein;

incubating the transformed yeast cells under conditions whereby the fusion protein is produced and cleaved to produce TFPI, wherein the TFPI is retained within the yeast cell;

preparing an insoluble fraction of the transformed yeast cells containing the TFPI; and

recovering the TFPI from the insoluble fraction,

wherein the TFPI comprises the N-terminal amino acid sequence shown in SEQ ID NO:7, ~~and~~  
wherein the TFPI has an inhibitory concentration of at least 1 µg/ml in a prothrombin clotting assay, and wherein the isolated and purified TFPI is free of mammalian proteins.

8-11. (Cancelled)

12. (Previously Presented) The isolated and purified TFPI of claim 7 wherein the yeast cell of the method is a *Saccharomyces cerevisiae* cell having a genotype selected from the group consisting of VH6, AB122, and JSC310.

13. (Previously Presented) The method of claim 7 wherein the second protein is ubiquitin.

14. (Previously Presented) The method of claim 7 wherein the second protein is superoxide dismutase.